Donor-specific antibody levels and three generations of crossmatches to predict antibody-mediated rejection in kidney transplantation

Transplantation. 2010 Jul 27;90(2):160-7. doi: 10.1097/tp.0b013e3181e36e08.

Abstract

Background: This study evaluated the prognostic impact of pretransplant donor-specific anti-human leukocyte antigen antibodies (DSA) detected by single-antigen beads and compared the three generations of crossmatch (XM) tests in kidney transplantation.

Methods: Thirty-seven T-cell complement-dependent cytotoxicity crossmatch (CXM) negative living donor kidney recipients with a retrospectively positive antihuman leukocyte antigen antibody screening assay were included. A single-antigen bead test, a flow cytometry XM, and a Luminex XM (LXM) were retrospectively performed, and the results were correlated with the occurrence of antibody-mediated rejections (AMRs) and graft function.

Results: We found that (1) pretransplant DSA against class I (DSA-I), but not against class II, are predictive for AMR, resulting in a sensitivity of 75% and a specificity of 90% at a level of 900 mean fluorescence intensity (MFI); (2) with increasing strength of DSA-I, the sensitivity for AMR is decreasing to 50% and the specificity is increasing to 100% at 5200 MFI; (3) the LXM for class I, but not for class II, provides a higher accuracy than the flow cytometry XM and the B-cell CXM. The specificity of all XMs is increased greatly in combination with DSA-I values more than or equal to 900 MFI.

Conclusions: In sensitized recipients, the best prediction of AMR and consecutively reduced graft function is delivered by DSA-I alone at high strength or by DSA-I at low strength in combination with the LXM or CXM.

MeSH terms

  • Adult
  • Female
  • Flow Cytometry
  • Graft Rejection / blood
  • Graft Rejection / diagnosis*
  • Graft Rejection / immunology
  • Graft Rejection / prevention & control
  • HLA Antigens / blood
  • HLA Antigens / immunology
  • Histocompatibility Testing / methods
  • Humans
  • Immunosuppression Therapy / methods
  • Isoantibodies / blood*
  • Kidney Transplantation / immunology*
  • Living Donors
  • Lymphocytes / immunology
  • Male
  • Middle Aged
  • Prognosis
  • ROC Curve
  • Reoperation / statistics & numerical data
  • Retrospective Studies
  • Tissue Donors

Substances

  • HLA Antigens
  • Isoantibodies